Skip to main content
OTCMKTS:SGTI

Shengtai Pharmaceutical Competitors

$0.02
0.00 (0.00 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$0.03
VolumeN/A
Average Volume8,568 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.71

Competitors

Shengtai Pharmaceutical (OTCMKTS:SGTI) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying SGTI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Shengtai Pharmaceutical, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Shengtai Pharmaceutical (OTCMKTS:SGTI) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Profitability

This table compares Shengtai Pharmaceutical and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shengtai PharmaceuticalN/AN/AN/A
AcusphereN/AN/AN/A

Volatility and Risk

Shengtai Pharmaceutical has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Shengtai Pharmaceutical and Acusphere, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shengtai Pharmaceutical0000N/A
Acusphere0000N/A

Earnings and Valuation

This table compares Shengtai Pharmaceutical and Acusphere's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shengtai PharmaceuticalN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Summary

Shengtai Pharmaceutical beats Acusphere on 1 of the 1 factors compared between the two stocks.

Shengtai Pharmaceutical (OTCMKTS:SGTI) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Shengtai Pharmaceutical and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shengtai PharmaceuticalN/AN/AN/A
AffymaxN/AN/AN/A

Risk & Volatility

Shengtai Pharmaceutical has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Shengtai Pharmaceutical and Affymax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shengtai Pharmaceutical0000N/A
Affymax0000N/A

Valuation & Earnings

This table compares Shengtai Pharmaceutical and Affymax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shengtai PharmaceuticalN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Summary

Affymax beats Shengtai Pharmaceutical on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Shengtai Pharmaceutical (OTCMKTS:SGTI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ARYx Therapeutics and Shengtai Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Shengtai Pharmaceutical0000N/A

Risk and Volatility

ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Shengtai Pharmaceutical has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Valuation & Earnings

This table compares ARYx Therapeutics and Shengtai Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
Shengtai PharmaceuticalN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and Shengtai Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
Shengtai PharmaceuticalN/AN/AN/A

Summary

Shengtai Pharmaceutical beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Shengtai Pharmaceutical (OTCMKTS:SGTI) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Valuation and Earnings

This table compares Shengtai Pharmaceutical and AtheroNova's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shengtai PharmaceuticalN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Shengtai Pharmaceutical and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shengtai Pharmaceutical0000N/A
AtheroNova0000N/A

Volatility and Risk

Shengtai Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, meaning that its stock price is 971% less volatile than the S&P 500.

Profitability

This table compares Shengtai Pharmaceutical and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shengtai PharmaceuticalN/AN/AN/A
AtheroNovaN/AN/AN/A

Summary

Shengtai Pharmaceutical beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Shengtai Pharmaceutical (OTCMKTS:SGTI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares China Botanic Pharmaceutical and Shengtai Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Shengtai PharmaceuticalN/AN/AN/A

Earnings and Valuation

This table compares China Botanic Pharmaceutical and Shengtai Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Shengtai PharmaceuticalN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for China Botanic Pharmaceutical and Shengtai Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Shengtai Pharmaceutical0000N/A

Risk & Volatility

China Botanic Pharmaceutical has a beta of 17.09, suggesting that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Shengtai Pharmaceutical has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats Shengtai Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Shengtai Pharmaceutical (OTCMKTS:SGTI) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Profitability

This table compares Shengtai Pharmaceutical and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shengtai PharmaceuticalN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Earnings and Valuation

This table compares Shengtai Pharmaceutical and China Dongsheng International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shengtai PharmaceuticalN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shengtai Pharmaceutical and China Dongsheng International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shengtai Pharmaceutical0000N/A
China Dongsheng International0000N/A

Volatility and Risk

Shengtai Pharmaceutical has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, suggesting that its share price is 1,238% more volatile than the S&P 500.

Summary

China Dongsheng International beats Shengtai Pharmaceutical on 1 of the 1 factors compared between the two stocks.


Shengtai Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Up
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00High Trading Volume
Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$31.58flat$0.00N/A0.00Gap Down
HRBR
Harbor Diversified
0.0$1.66flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00Gap Up
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.02flat$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00News Coverage
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.